Moderna Stock Price, News & Analysis

Moderna, Inc. (Nasdaq: MRNA) announced the publication of data in The New England Journal of Medicine showcasing the persistent antibody response achieved by its COVID-19 vaccine six months post-second dose. The study involved 33 participants from a Phase 1 trial, confirming robust antibody levels, aligning with prior findings on natural COVID-19 immunity. Ongoing studies will further evaluate immune responses. Moderna is also advancing its clinical strategy to combat emerging variants and enhance vaccine efficacy as part of its commitment to addressing the pandemic.

Moderna and Catalent have expanded their strategic collaboration, dedicating a new high-speed vial filling line at Catalent's Bloomington facility for the production of the Moderna COVID-19 Vaccine. This expansion follows a successful milestone of 100 million doses achieved in March 2021. The new line will support not only the COVID-19 vaccine but also other investigational programs in Moderna's pipeline until June 2023. Catalent's investment of $50 million will enhance manufacturing capabilities and expedite project timelines.

Moderna (Nasdaq: MRNA) announced FDA authorization allowing the COVID-19 vaccine to be stored at room temperature for 24 hours, an increase from 12 hours, and a punctured vial can now be used for up to 12 hours instead of 6. Additionally, FDA approved new vial presentations for 11 and 15 doses. This change aims to facilitate easier administration and improve vaccine access. The company is committed to optimizing production to enhance vaccine distribution while maintaining quality and safety.

Ximedica has partnered with Moderna (Nasdaq: MRNA) to create a prototype for rapid mobile vaccine and therapeutic manufacturing under DARPA's Nucleic Acids On-Demand World-Wide Program. The collaboration, which spans four years, aims to develop a mobile platform that can quickly diagnose and respond to pathogen threats. Ximedica will receive up to $11 million in funding for this initiative. The project envisions manufacturing units that can produce hundreds of doses in just days, ensuring timely medical responses in remote locations worldwide.

Moderna (Nasdaq: MRNA) has announced its upcoming virtual Vaccines Day for analysts and investors, scheduled for 8:00 a.m. ET on April 14. The event will feature presentations from management and key opinion leaders discussing Moderna’s mRNA vaccines and vaccine development considerations. A live webcast will be available in the Investors section of the Moderna website, with a replay archived for one year. Moderna is recognized for its innovative mRNA platform and has developed several vaccines and therapeutics, including an effective COVID-19 vaccine.

Moderna, Inc. (Nasdaq: MRNA) announced shipping its 100-millionth COVID-19 vaccine dose to the U.S. government, with over 67 million doses administered in the U.S. Moderna's production has surged since receiving Emergency Use Authorization from the FDA in December 2020, increasing monthly shipments to a total of 88 million doses for Q1 2021. The company plans to maintain a shipment rate of 40-50 million doses per month. Moderna's COVID-19 vaccine, developed with the National Institute of Allergy and Infectious Diseases, is authorized for emergency use in individuals aged 18 and older.

Moderna, Inc. (Nasdaq: MRNA) has announced a new supply agreement with the Philippines for an additional 7 million doses of its COVID-19 Vaccine, bringing the total confirmed order to 20 million doses. This agreement, supported by the private sector, will help address vaccine access in the Philippines. Currently, the vaccine is not approved for use in the country, and Moderna will seek necessary regulatory approvals. Initial procurement of 13 million doses was announced on March 6, 2021, with deliveries set to commence in mid-2021.

Moderna Inc. (Nasdaq: MRNA) has initiated the Phase 2/3 KidCOVE study for its COVID-19 vaccine, mRNA-1273, in children aged 6 months to under 12 years. This study, involving approximately 6,750 participants in the U.S. and Canada, aims to evaluate the vaccine's safety, tolerability, and effectiveness. The study will consist of two parts: an open-label dose-escalation and a randomized placebo-controlled phase. Interim analysis will determine appropriate dosing. Moderna's vaccine has already been administered to 17.8 million adults in the U.S., underscoring its established efficacy.

Moderna (Nasdaq: MRNA) has commenced dosing the first participants in a Phase 1 study of mRNA-1283, its next-generation COVID-19 vaccine. This study aims to evaluate the safety and immunogenicity of mRNA-1283, which could offer refrigerator stability for easier distribution. The trial will assess three dose levels (10 µg, 30 µg, 100 µg) in a two-dose format, and a 100 µg single dose. The vaccine targets key regions of the SARS-CoV-2 spike protein. Moderna continues its commitment to addressing public health challenges with innovative solutions.